srch

28.07.2021 · BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ...

Boston Pharmaceuticals leverages a highly experienced drug development team to generate clinical data to create value for their organization and their partners. They have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for their diverse pipeline.

06.12.2021 · BOSTON, MA / ACCESSWIRE / December 6, 2021 / Block & Leviton is investigating Reata Pharmaceuticals, Inc. (NASDAQ:RETA) for potential securities law violations.Investors who have lost money in ...

Boston Pharmaceuticals Investors. Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info; This information is available in the PitchBook Platform. To explore Boston Pharmaceuticals‘s full profile, request access. Request a free trial. Boston Pharmaceuticals Investments (2) Company Name Deal Date

Boston Pharmaceuticals leverages a highly experienced drug development team to generate clinical data to create value for their organization and their ...

Investor Relations. Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation ... Boston, MA 02110 (617) 420-5698.

November 19, 2015: Gurnet Point Capital, an investment firm focused on the ... Boston Pharmaceuticals is agnostic to therapeutic area specialization, ...

11.11.2021 · HOLBAEK, Denmark, Nov. 11, 2021 /PRNewswire/ -- Pharmacosmos Group, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, today announced the acquisition of AbFero Pharmaceuticals, Inc., a Boston based, privately-held clinical stage pharmaceutical company dedicated to treating diseases of …

... Boston Pharma says it is a fully integrated drug development company with a $600 million commitment from Gurnet, a healthcare investment ...

27.10.2021 · Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital. ... Cardurion Pharmaceuticals has facilities in Boston, Massachusetts and Shonan, Japan.

26.04.2021 · Boston Pharmaceuticals is a portfolio company of Waypoint Capital, an investment firm based in Europe and focused on healthcare, medical technologies, and asset management. For more information, please visit www.bostonpharmaceuticals.com or follow us on Twitter @BosPharma and LinkedIn.

Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for …

27.12.2021 · BOSTON, MA / ACCESSWIRE / December 27, 2021 / Block & Leviton announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (NASDAQ: RETA) for potential securities law ...

See the top 20 Pharmaceuticals Pre Seed investors in Boston / New England as voted by the startup community. VCs from Realist Ventures, KdT Ventures, ...

Boston Pharmaceuticals is a portfolio company of Gurnet Point Capital, a Cambridge, MA based private equity firm focused on healthcare investing.

Boston Pharmaceuticals returned ARN-6039 or BOS-172767 to Arrien Pharmaceuticals in January 2021 and the company successfully relicensed to Xenter, Inc., in June 2021. Our initial licensing of ARN-6039 to Boston Pharmaceuticals, subsequently to Xenter, Inc., was encouraging, and further validates ARN-6039 importance in targeting ROR-γt/IL-17 axis.

A new company, Boston Pharmaceuticals, has been created by Gurnet Point Capital, the investment firm formed earlier this year by Swiss ...

Information on valuation, funding, acquisitions, investors, and executives for Boston Pharmaceuticals. Use the PitchBook Platform to explore the full ...

Transforming the right molecules into the best medicines™. Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines ...